Company profile
Black Bird Biotech, Inc.
OTC: BBBT · Healthcare · Drug Manufacturers - Specialty & Generic
#1054 of 1,422 Healthcare companies by revenue27th-percentile growth
EA Score
——FH —DQ 16GM —SS 34
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, listing tenure · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$36.3k
Rev growth YoY (TTM)
-61.0%
Net income (FY)
-$1.7M
Employees
4
as of 2026-08-28
Market cap
$98.4k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$82.6k$82.6k2022
Net income-$1.7M-$1.7M2022
Operating income-$1.3M-$1.3M2022
Total assets$218.5k$218.5k2022
Liabilities$868.7k$868.7k2022
Equity-$650.2k-$650.2k2022
Revenue trend
FY2012 – FY2022 · USD
FY12
FY20
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Black Bird Biotech, Inc.’s revenue?
Black Bird Biotech, Inc. booked $82.6k in FY2022 revenue, contracting 21% year over year — slower than 73% of Healthcare companies we track, at a -2009.1% net margin.
Peers · Healthcare
Citius Pharmaceuticals, Inc.42DAIM ImmunoTech Inc.36DZecotek Photonics Inc.——U.S. Stem Cell, Inc.——Sera Prognostics, Inc.41DXebra Brands Ltd.——Neighbors
Denton →Key facts
CEONelson Grist
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersArgyle, TX
ExchangeOTC: BBBT
Employees4
IPO date2009-11-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.